SCHEMBL31200554

SCHEMBL31200554

CC(C)(C)OC(=O)N1CCC2CCCNC2C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.46
MBTD1 Q05BQ5 1/20 0.45
L3MBTL3 Q96JM7 1/20 0.45
GPR119 Q8TDV5 6/20 0.44
EPHX1 P07099 1/20 0.44
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
KMT2A Q03164 1/20 0.42
PREP P48147 2/20 0.42
RECQL P46063 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
NR1H2 P55055 1/20 0.40
KDM4E B2RXH2 1/20 0.40
THRB P10828 1/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17228504 0.92 HPGD (0.46) HPGDMBTD1L3MBTL3GPR119EPHX1
SCHEMBL30923125 0.92 GPR119 (0.46) HPGDGPR119EPHX1MAPTRECQL
SCHEMBL3650512 0.92 NR1H2 (0.49) HPGDMBTD1L3MBTL3GPR119EPHX1
SCHEMBL29208875 0.92 NR1H2 (0.49) HPGDMBTD1L3MBTL3GPR119EPHX1
SCHEMBL18239343 0.92 NR1H2 (0.49) HPGDMBTD1L3MBTL3GPR119EPHX1
SCHEMBL23700689 0.92 GPR119 (0.46) HPGDGPR119EPHX1MAPTRECQL
SCHEMBL20186727 0.92 GPR119 (0.46) HPGDGPR119EPHX1MAPTRECQL
SCHEMBL22689240 0.92 NR1H2 (0.49) HPGDMBTD1L3MBTL3GPR119EPHX1
SCHEMBL22695207 0.92 NR1H2 (0.49) HPGDMBTD1L3MBTL3GPR119EPHX1
SCHEMBL28585750 0.87 PREP (0.45) HPGDGPR119EPHX1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-10-31 US disclosed
WO-2024188994-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES SANOFI (FR) 2024-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360151-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES NLRP3, NOD1, NLRP1 HPGD 1295/4885MBTD1 3425/4885L3MBTL3 3699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.